QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

5 medical stocks growing earnings by triple digits

Medical stocks

Key Points

  • The healthcare sector is quickly heating up in all the fundamental ways professional traders seek. 
  • Within it, you can spot five stocks calling for new moves to the upside, backed by similar tailwinds.
  • Analysts see the same factors at play and boldly project triple-digit EPS growth in all of them.
  • 5 stocks we like better than Axsome Therapeutics

While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy. 

Big traders and investors at places like The Goldman Sachs Group NYSE: GS and other respectable investment houses tend to employ a process called ‘top-down’ analysis, where the fundamental trends of an industry and the economy itself are taken into account to select winning stocks, but more on what that picture is looking like today in just a bit.

For now, all you need to worry about is that medical stocks are becoming more and more attractive today; names like Vericel NASDAQ: VCEL, Axsome Therapeutics NASDAQ: AXSM, and three other worthy peers can quickly become just the thing that these traders and investors look for to deploy their available investment dollars to squeeze alpha out of the market.

Don’t fight the market

Following the past quarterly trend in the ISM services PMI reports, you will notice that the healthcare sector has pushed out three consecutive months of expansionary activity. This means that the odds are high for stocks in that space to report higher quarterly earnings per share. Not only that, healthcare was the largest expanding sector for January.


The PMI is one of the first leading indicators that these investors look into for generating ideas. Still, it is only a fraction of the entire picture. Understanding this next indicator can also help you understand why this sector will attract all the heat in the following months.

Employment trends can give you another idea of what the economy is doing lately, and the latest employment situation report says a lot about the healthcare space. Healthcare companies added 70.3 thousand jobs in the past month, whereas the entire U.S. economy added 353 thousand; that’s almost 20% of all new hires!

Because of these heating metrics, markets are looking to these stocks to make a decent profit. But you cannot just take the fundamental story at face value and go punting your money blindly into any stock just because it operates in the sector, so here is how you can make better picks.

Two things drive professional traders to pick stocks once they decide on the sector. First, they prefer to see positive outliers in the next twelve months of earnings per share projections; who doesn’t like growth, right? Secondly, stocks that are set to grow typically command a higher valuation multiple, so you also need to see positive outliers calling for premium valuations.

Know when to hold ‘em

Knowing what you know now, it shouldn’t be a surprise to see these peers commanding higher valuations based on how explosive their earnings are set to grow. Vericel analysts see earnings growing by as much as 366.0% for the next twelve months, significantly above the 15.1% industry average.

This is why the stock trades at a forward P/E ratio of 76.6x, representing a 333.0% premium to the sector’s average 17.7x valuation. With Axsome, the story is not too far away either, with analysts projecting a 130.9% EPS advance in the next year, calling for a 415.0% premium valuation with its 91.0x forward P/E.

Other names worthy of mention are Argenx NASDAQ: ARGX, Azenta NASDAQ: AZTA, and even Inari Medical NASDAQ: NARI. You can probably guess what these stocks all have in common, right? Triple-digit EPS growth rates, premium valuations to the sector, and positive outliers within an industry that is quickly heating up.

Argenx analysts think that the stock could grow its earnings by as much as 243.0% in the next year; markets don’t think this is far from reality as they are willing to pay a 479.0% premium to the sector through its 102.4x forward P/E valuation. These same analysts set a $525.9 share price target on the stock, which still implies a 33.7% upside from today’s prices.

Azenta brings another interestingly bullish outlook from analysts, as they want to see EPS advance by 136.0%, a fact that traders have bid up to a 534.0% premium to the rest of the group, willing to pay a staggering 112.0x forward P/E multiple. There is a bullish trend in the industry, right?

Last but not least, the group's most ‘expensive’ name is Inari Medical, but remember the saying, “It must be expensive for a reason.” The reason behind it is, well, really straightforward. Analysts boldly project earnings to jump by 390.0% this year, justifying a 199.7x forward P/E multiple; otherwise, there will be a 1,000.0% premium to the sector.

Analysts feel comfortable with these projections, as the price target has been set at $81.3 a share, showing that this name could go higher by 43.7% from where it trades today.

Congratulations on the top-down; the list quickly grows significant for the stocks that can quickly become trader favorites and see the right price action very soon.

→ Critical asset just had biggest fall on record (From Stansberry Research) (Ad)

Should you invest $1,000 in Axsome Therapeutics right now?

Before you consider Axsome Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.

While Axsome Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
The Goldman Sachs Group (GS)
4.6807 of 5 stars
$393.18+1.3%2.80%17.23Moderate Buy$409.93
Vericel (VCEL)
0.7982 of 5 stars
$47.80-0.4%N/A-207.83Buy$44.40
argenx (ARGX)
3.2556 of 5 stars
$397.70-3.3%N/A-95.60Moderate Buy$526.29
Azenta (AZTA)
2.1773 of 5 stars
$65.21+0.2%N/A-210.35Moderate Buy$74.67
Inari Medical (NARI)
1.9054 of 5 stars
$58.260.0%N/A-971.00Moderate Buy$81.29
Axsome Therapeutics (AXSM)
4.4239 of 5 stars
$82.95-1.3%N/A-15.95Moderate Buy$116.10
Compare These Stocks  Add These Stocks to My Watchlist 

Gabriel Osorio-Mazilli

About Gabriel Osorio-Mazilli

  • gosoriomazzilli@gmail.com

Contributing Author

Value Stocks, Asian Markets, Macro Economics

Experience

Gabriel Osorio-Mazilli has been a contributing writer for MarketBeat since 2023.

Areas of Expertise

Value investing, long/short trading, options, emerging markets

Education

CFA Level I candidate; Goldman Sachs corporate training; independent courses

Past Experience

Analyst at Goldman Sachs, associate at Citigroup, senior financial analyst in real estate


Featured Articles and Offers

Search Headlines: